Nephrocare up 7% on debut; Park Medi World slips at listing

Two IPOs hit Dalal Street today, Nephrocare Health Services and Park Medi World, delivering a tale of two debut performances on the same listing day in Mumbai. Nephrocare kicked off trading with a decent showing, while Park Medi World faced a cooler reception, trading below its issue price on both major exchanges. Nephrocare Health Services priced its shares in the Rs 438-460 band and offered a lot of 32 shares. The stock made a decent debut, reportedly listing with a 7% premium to the upper end of its price band, suggesting solid interest from investors in the hospital network’s growth potential. Park Medi World, meanwhile, priced its shares in the Rs 154-162 range with a lot size of 92 shares and saw a different story on listing day. The stock listed at Rs 155.60 on BSE, a discount of 3.95% to the Rs 162 issue price, and at Rs 158.80 on NSE, about 1.98% below the upper band. Ahead of the listing, the grey market had priced the stock at a premium of Rs 4-5 per share, hinting at a possible listing pop of around 3%. Retail investors who received a single lot of 92 shares for Park Medi World faced a paper loss of roughly Rs 588.80 on the listing day, while HNIs who held 14 lots (1,196 shares) faced losses of about Rs 8,243.20. The Park Medi World IPO raised about Rs 920 crore in total, comprising fresh shares worth Rs 770 crore and an offer-for-sale of up to Rs 150 crore, with the issue subscribed 8.10 times overall. QIBs were bid up 11.48 times and non-institutional investors (NIIs) subscribed 15.15 times. The combined listing activity underlines the differing appetite among investors for hospital services versus a potentially broader health-care platform, and it will be watched for post-listing performance and fundamentals. Nephrocare’s 32-share lot and a 7% premium on debut add a contrasting note to Park Medi World’s discount-driven start, illustrating the varied dynamics that govern IPOs in today’s market.

#IPOWatch #MarketDebut #DalalStreet